March 13, 2015
SAN FRANCISCO -- Equities' small fry are jamming the same day the big stocks are clamming up.?
You can see it posted across the micro-cap and small-cap charts that measure
small-company stocks.
?So what?
Here's what. You can ride in this little-cap wagon. But it's picky.
?The small-fry stock, and the emerging companies that grow behind? private-equity curtains, are hit and miss. (Their axles are dragging.)
Picking the winners almost always results in agony for most individual investors.
So unlike like the blue-chips worldwide. The mother-hunker stocks such as Lockheed-Martin have given all of the world's "smart and safe" investors a multinational moon shot for at least seven years now. With dividends.
I'm a small stock investor, a small stock researcher and a small stock supporter: resources, biomedicals, emerging technologies.
As for the
suffering part: you can read it for free and get a laugh, either here --
So Long, So Small -- or
there -- or via
MicroCap Review's
just-published edition.
So much for the agony. I think any of us around the world who support the scrap pile (if public: $200 million market caps and lower; if private: $50 million and lower) will have some good pickings the next two or three years.
We deserve it.
I call what is coming, or what I think is coming, a
small-fry melt-up. It has to do with selective buying. It has to do with cheap energy. It has to do with banks and lenders and static capital knowing the big-beefy profits on the Fortune 4,000 companies (my term) are over. Or just about finished.
?So for free (and the paid subscribers at
TCR always get this material first and in great detail), here are three to look at next week; I think they are actionable:
--
Sysorex Global Holdings (SYRX on NASDAQ)?: I think there will be fundamental news from the Silicon Valley computer systems integrator. I don't know if we will see a white-paper from the company's
AirPatrol unit on its VLE beacon technology -- mobile tracking of portable devices. Or solid indications of fresh contracts with casinos, entertainment parks, shopping mall operators. I have been buying more in the $1.25 to $1.50 USD range here.
-- RiceBran Technologies (RIBT on NASDAQ): This one, I am told, is "all about the guidance it gives." The Arizona maker of derivative rice bran products can be seen at such razzle-dazzle gatherings as
Pet Food Forum. The company stubbed its financial toe about a year ago and looks like its sales and gross margins are growing smartly again. To say the next quarterly financial, due out any day now, will bear fruit is about where I am at with this one. I am looking at purchasing the shares, whose market cap equals its revenue rate of about $40 million yearly.
-- BioCryst Pharmaceuticals (BCRX on NASDAQ): Yes, this one is a lot greater than $200 million market value. BioCryst is on the cusp of something big in the world of treatable diseases such as influenza and other lethal viruses. The stock is active, and I own a bunch. I think BCRX could get bought by a much larger pharma in coming years. Severe flu, leukemia, hereditary angioedema and more.
Look for me at MicroCap Review's
Growth Capital Expo in Las Vegas, mid-April. It's 2-plus days of
IPO boot camp for newbies and a thorough scrubbing for the public small-fry. Compelling, for me, will be the presence of some motivated investors from Mexico, Asia and the Emirates ... small and mid-sized funds and fat cats chasing 150 or so fresh ideas, public and private. It's a mini-
Roth, if you know what I mean: you have time to breathe between events.
There. I knew I could get through 800 words without mentioning
gold. Or
mother-lode (one of which I am looking at seriously in Colorado).
?
-- Thom Calandra
THE CALANDRA REPORT: Subscribe
Now $139 yearly!
See: a thomcalandra.com home for our expanding TCR family.
THE CALANDRA REPORT
$139: Will Recur Yearly
Thom Calandra & TCR are researchers and investors. They are not registered investment advisers. The research and material they offer to subscribers are meant as editorial opinion.